AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aurinia Pharmaceuticals Receives Buy Rating and Target Price of $17
ByAinvest
Wednesday, Jul 30, 2025 11:13 pm ET1min read
Aurinia Pharmaceuticals (AUPH) has received a Buy rating and a $17 target price from H.C. Wainwright analyst Arthur He. The company's successful lupus nephritis franchise and solid financial health, including a 28.1% year-over-year revenue growth and 16.11% net margin, support this positive outlook. Aurinia's innovative product offerings and strategic focus on autoimmune diseases also contribute to its promising future.
Aurinia Pharmaceuticals (AUPH) has received a Buy rating and a $17 target price from H.C. Wainwright analyst Arthur He. The company's robust financial performance and strategic focus on autoimmune diseases have driven this positive outlook. Aurinia's successful lupus nephritis franchise and solid financial health, including a 28.1% year-over-year revenue growth and 16.11% net margin, support this rating [1].Aurinia's innovative product offerings and strategic focus on autoimmune diseases also contribute to its promising future. The company's recent Phase 1 study results of aritinercept, an immunotherapy, demonstrate its commitment to advancing innovative therapies. Despite facing setbacks such as being dropped from several Russell indexes, Aurinia has pivoted to profitability, showcasing a notable increase in quarterly revenue and net income [1].
Aurinia is scheduled to announce its Q2 earnings results on Thursday, July 31st, with the consensus EPS estimate at $0.14 and revenue estimate at $64.27M (+12.4% Y/Y). Over the last 2 years, AUPH has beaten EPS estimates 88% of the time and revenue estimates 63% of the time [2].
The company's financial turnaround is underpinned by robust annual revenue growth projected at 12.2% and earnings growth forecast at 25.8%, outpacing broader market expectations. These figures underscore Aurinia's recovery trajectory and innovation prowess [1].
References:
[1] https://finance.yahoo.com/news/us-high-growth-tech-stocks-173820877.html
[2] https://seekingalpha.com/news/4474388-aurinia-pharma-q2-2025-earnings-preview
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet